Ipswich Investment Management Co. Inc. cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 47,478 shares of the company’s stock after selling 2,986 shares during the period. Johnson & Johnson accounts for approximately 1.9% of Ipswich Investment Management Co. Inc.’s portfolio, making the stock its 12th largest position. Ipswich Investment Management Co. Inc.’s holdings in Johnson & Johnson were worth $7,442,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of JNJ. Tower View Wealth Management LLC raised its holdings in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the period. Keener Financial Planning LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $40,000. Creative Capital Management Investments LLC raised its holdings in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares during the period. Altshuler Shaham Ltd raised its holdings in Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after buying an additional 87 shares during the period. Finally, Mizuho Securities Co. Ltd. raised its holdings in Johnson & Johnson by 216.7% in the third quarter. Mizuho Securities Co. Ltd. now owns 380 shares of the company’s stock valued at $59,000 after buying an additional 260 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on JNJ
Johnson & Johnson Stock Down 1.2 %
Shares of NYSE:JNJ opened at $146.82 on Friday. The firm has a market cap of $353.80 billion, a PE ratio of 9.15, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The company has a fifty day simple moving average of $155.47 and a 200 day simple moving average of $155.41. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.68 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- What is a Low P/E Ratio and What Does it Tell Investors?
- Hasbro’s Management Made All the Right Calls This Quarter
- What Do S&P 500 Stocks Tell Investors About the Market?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Which Wall Street Analysts are the Most Accurate?
- Power Surge: Utilities Sector’s Resilience Shines
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.